NASDAQ:IMRX

Immuneering (IMRX) Stock Forecast, Price & News

$10.60

+0.34 (+3.31%)

(As of 01:28 PM ET)

Compare

Today's Range: $10.08
▼
$10.84
50-Day Range: $6.49
▼
$13.36
52-Week Range: $3.70
▼
$16.17

Volume: 22,723 shs
Average Volume: 59,280 shs
Market Capitalization: $310.05 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $18.67

Immuneering MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 76.1% Upside
$18.67 Price Target
Short Interest: Bearish
7.42% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.15) to ($2.12) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.79 out of 5 stars

Medical Sector

716th out of 986 stocks

Pharmaceutical Preparations Industry

339th out of 480 stocks

3.3

Analyst's Opinion

Consensus Rating
Immuneering has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $18.67, Immuneering has a forecasted upside of 76.1% from its current price of $10.60.
Amount of Analyst Coverage
Immuneering has only been the subject of 3 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
7.42% of the float of Immuneering has been sold short.
Short Interest Ratio / Days to Cover
Immuneering has a short interest ratio ("days to cover") of 24, which indicates bearish sentiment.
Change versus previous month
Short interest in Immuneering has recently increased by 25.60%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Immuneering does not currently pay a dividend.
Dividend Growth
Immuneering does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for IMRX.

2.4

News and Social Media Coverage

News Sentiment
Immuneering has a news sentiment score of 1.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Immuneering this week, compared to 1 article on an average week.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Immuneering insiders have not sold or bought any company stock.
Percentage Held by Insiders
23.90% of the stock of Immuneering is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
45.70% of the stock of Immuneering is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Immuneering are expected to grow in the coming year, from ($2.15) to ($2.12) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Immuneering is -5.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Immuneering is -5.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Immuneering has a P/B Ratio of 2.55. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Immuneering (NASDAQ:IMRX) Stock

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.

Receive IMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immuneering and its competitors with MarketBeat's FREE daily newsletter.

IMRX Stock News Headlines

June 5, 2023 | finance.yahoo.com

Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial for RAS-Mutant, Advanced Solid Tumors

May 5, 2023 | finance.yahoo.com

Immuneering Corporation (IMRX) Reports Q1 Loss, Misses Revenue Estimates

June 9, 2023 | Edge On The Street (Ad)

Graphite versus Lithium - What Investors Should Know

Over 18 million EVs will be cruising U.S roads by 2030. And every one million EVs manufactured will require 82,000 tons of the metal graphite for their batteries. That's a total of 1,476,000 tons of graphite! Graphite is actually the largest component of EV batteries - NOT lithium. Experts warn of a massive graphite shortfall, especially since North America currently has no operating graphite mines.

May 4, 2023 | finance.yahoo.com

Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates

May 4, 2023 | markets.businessinsider.com

Mizuho Securities Sticks to Its Buy Rating for Immuneering (IMRX)

May 2, 2023 | americanbankingnews.com

Short Interest in Immuneering Co. (NASDAQ:IMRX) Rises By 6.1%

April 25, 2023 | americanbankingnews.com

Chardan Capital Weighs in on Immuneering Co.'s FY2023 Earnings (NASDAQ:IMRX)

April 21, 2023 | benzinga.com

Is Immuneering Corp (IMRX) a Stock to Watch After Gaining 4.09% This Week?

June 9, 2023 | PressReach (Ad)

This Stock's Worth Researching

Uncover the buzz behind this trending stock. Read the comprehensive report here.

April 21, 2023 | americanbankingnews.com

Q2 2023 EPS Estimates for Immuneering Co. (NASDAQ:IMRX) Increased by Oppenheimer

April 20, 2023 | msn.com

Morgan Stanley Upgrades Immuneering Corp (IMRX)

April 20, 2023 | msn.com

Mizuho Upgrades Immuneering Corp (IMRX)

April 20, 2023 | americanbankingnews.com

Immuneering (NASDAQ:IMRX) PT Raised to $22.00

April 19, 2023 | msn.com

Immuneering Picks Up New Kudos but Still Falters

April 19, 2023 | msn.com

What 7 Analyst Ratings Have To Say About Immuneering

April 19, 2023 | markets.businessinsider.com

Immuneering (IMRX) was upgraded to a Hold Rating at Morgan Stanley

April 19, 2023 | msn.com

Immuneering gains as Morgan Stanley, Mizuho upgrade on lead asset

April 19, 2023 | americanbankingnews.com

Immuneering (NASDAQ:IMRX) Upgraded at Morgan Stanley

April 19, 2023 | americanbankingnews.com

Immuneering (NASDAQ:IMRX) Stock Rating Upgraded by Mizuho

April 19, 2023 | markets.businessinsider.com

Immuneering (IMRX) was upgraded to a Buy Rating at Mizuho Securities

April 18, 2023 | finance.yahoo.com

Immuneering Announces $30 Million Underwritten Offering

April 12, 2023 | finance.yahoo.com

Immuneering to Present at the 22nd Annual Needham Virtual Healthcare Conference

April 11, 2023 | finance.yahoo.com

Immuneering Corporation (IMRX) Surges 18.5%: Is This an Indication of Further Gains?

April 5, 2023 | finance.yahoo.com

Immuneering to Present Initial Phase 1 Pharmacokinetic, Pharmacodynamic Modeling and Safety Data for Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023

March 31, 2023 | americanbankingnews.com

Immuneering (NASDAQ:IMRX) Now Covered by Mizuho

March 31, 2023 | msn.com

Mizuho Initiates Coverage of Immuneering (IMRX) with Neutral Recommendation

March 29, 2023 | markets.businessinsider.com

Immuneering (IMRX) Receives a New Rating from Mizuho Securities

See More Headlines

IMRX Price History

30 days | 90 days | 365 days | Advanced Chart

IMRX Company Calendar

Last Earnings: 11/08/2021
Today: 6/09/2023
Next Earnings (Estimated): 8/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:IMRX
CUSIP: N/A
CIK: 1790340
Web: www.immuneering.com
Phone: 617-500-8080
Fax: N/A
Employees: 64
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $18.67
High Stock Price Forecast: $22.00
Low Stock Price Forecast: $14.00
Forecasted Upside/Downside: +77.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.94)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-50,510,000.00
Net Margins: -15,934.70%
Pretax Margin: -38,512.78%
Return on Equity: -44.23%
Return on Assets: -40.50%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 17.05
Quick Ratio: 17.05

Sales & Book Value

Annual Sales: $320,000.00
Price / Sales: 960.68
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.16 per share
Price / Book: 2.53

Miscellaneous

Outstanding Shares: 29,250,000
Free Float: 22,258,000
Market Cap: $307.42 million
Optionable: Not Optionable
Beta: -1.35

Key Executives

Dr. Benjamin J. Zeskind M.B.A. (Age 39)
MBA, Ph.D., Co-Founder, Pres, CEO & Director
Comp: $839.77k

Dr. Brett M. Hall Ph.D. (Age 54)
Chief Scientific Officer
Comp: $819.69k

Ms. Mallory Morales CPA (Age 39)
VP of Fin., Principal Financial & Accounting Officer and Treasurer

Ms. Paula George CPA
Sr. Mang. of Accounting & Operations

Mr. Michael D. Bookman J.D. (Age 34)
Gen. Counsel & Sec.

Ms. Leah R. Neufeld
Chief People Officer

Dr. Scott Barrett M.D. (Age 59)
Chief Medical Officer

Dr. Mohamedi Kagalwala M.B.A.
Ph.D., Head of Neuroscience Devel.

Dr. Peter King Ph.D.
Head of Discovery & VP

Dr. Rajaraman Krishnan Ph.D.
Head of Neuroscience Discovery

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

IMRX Stock - Frequently Asked Questions

Should I buy or sell Immuneering stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immuneering in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IMRX shares.
View IMRX analyst ratings or view top-rated stocks.
What is Immuneering's stock price forecast for 2023?: 3 Wall Street research analysts have issued 1 year price targets for Immuneering's shares. Their IMRX share price forecasts range from $14.00 to $22.00. On average, they anticipate the company's share price to reach $18.67 in the next year. This suggests a possible upside of 77.6% from the stock's current price.
View analysts price targets for IMRX or view top-rated stocks among Wall Street analysts.
How have IMRX shares performed in 2023?: Immuneering's stock was trading at $4.85 at the start of the year. Since then, IMRX stock has increased by 116.7% and is now trading at $10.51.
View the best growth stocks for 2023 here.
Are investors shorting Immuneering?: Immuneering saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 1,570,000 shares, an increase of 25.6% from the April 30th total of 1,250,000 shares. Based on an average daily trading volume, of 65,400 shares, the days-to-cover ratio is currently 24.0 days. Currently, 7.4% of the shares of the company are short sold.
View Immuneering's Short Interest.
When is Immuneering's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our IMRX earnings forecast.
How were Immuneering's earnings last quarter?: Immuneering Co. (NASDAQ:IMRX) issued its quarterly earnings results on Monday, November, 8th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.57) by $0.10. The business had revenue of $0.48 million for the quarter, compared to analyst estimates of $0.70 million. Immuneering had a negative trailing twelve-month return on equity of 44.23% and a negative net margin of 15,934.70%.

When did Immuneering IPO?: (IMRX) raised $105 million in an IPO on Friday, July 30th 2021. The company issued 7,000,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Jefferies, Cowen and Guggenheim Securities acted as the underwriters for the IPO.
What is Immuneering's stock symbol?: Immuneering trades on the NASDAQ under the ticker symbol "IMRX."
Who are Immuneering's major shareholders?: Immuneering's stock is owned by a variety of retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (11.82%), BlackRock Inc. (4.58%), FMR LLC (1.38%), ExodusPoint Capital Management LP (0.30%), Susquehanna International Group LLP (0.20%) and Jane Street Group LLC (0.16%). Insiders that own company stock include Ann E Berman, Benjamin J Zeskind, Biren Amin, Brett Matthew Hall, Laurie Keating, Michael Bookman and Scott Barrett.
View institutional ownership trends.
How do I buy shares of Immuneering?: Shares of IMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Immuneering's stock price today?: One share of IMRX stock can currently be purchased for approximately $10.51.
How much money does Immuneering make?: Immuneering (NASDAQ:IMRX) has a market capitalization of $307.42 million and generates $320,000.00 in revenue each year. The company earns $-50,510,000.00 in net income (profit) each year or ($1.94) on an earnings per share basis.
How can I contact Immuneering?: The official website for the company is www.immuneering.com. The company can be reached via phone at 617-500-8080 or via email at afields@rxir.com.

This page (NASDAQ:IMRX) was last updated on 6/9/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Immuneering (IMRX) Stock Forecast, Price & News

Immuneering MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Company Ownership

Earnings and Valuation

About Immuneering (NASDAQ:IMRX) Stock

IMRX Stock News Headlines

IMRX Price History

IMRX Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

IMRX Stock - Frequently Asked Questions

Overall MarketRank^™